Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Debt: 2020-2025

Historic Total Debt for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Total Debt rose 71.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 71.99%. This contributed to the annual value of $228,000 for FY2024, which is 90.15% down from last year.
  • Insight Molecular Diagnostics' Total Debt amounted to $1.1 million in Q3 2025, which was up 53.27% from $689,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Total Debt high stood at $12.3 million for Q2 2021, and its period low was $109,000 during Q3 2022.
  • For the 3-year period, Insight Molecular Diagnostics' Total Debt averaged around $694,000, with its median value being $523,500 (2024).
  • Per our database at Business Quant, Insight Molecular Diagnostics' Total Debt slumped by 95.48% in 2022 and then skyrocketed by 2,022.94% in 2023.
  • Insight Molecular Diagnostics' Total Debt (Quarterly) stood at $1.4 million in 2021, then slumped by 92.15% to $109,000 in 2022, then skyrocketed by 2,022.94% to $2.3 million in 2023, then crashed by 90.15% to $228,000 in 2024, then spiked by 71.99% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $689,000 for Q2 2025, and $433,000 during Q1 2025.